Clinical Characteristics of Inpatients with Schizophrenia Spectrum Disorder Treated with Electroconvulsive Therapy: A Population-Level Cross-Sectional Study: Titre: Caractéristiques cliniques des patients hospitalisés présentant un trouble du spectre de la schizophrénie et traités par électrochocs : Une étude de population transversale DOI
Tyler S. Kaster,

Amreen Babujee,

Isobel Sharpe

et al.

The Canadian Journal of Psychiatry, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 11, 2024

Electroconvulsive therapy (ECT) is an evidence-based treatment for schizophrenia when anti-psychotic medications do not sufficiently control symptoms of psychosis or rapid response required. Little known about how it used in routine clinical practice. The aim this study was to identify the association demographic and characteristics with administration ECT spectrum disorders (SSD).

Language: Английский

Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety DOI Creative Commons
Carlos De las Cuevas, Emílio J. Sanz, José de León

et al.

Patient Preference and Adherence, Journal Year: 2024, Volume and Issue: Volume 18, P. 2261 - 2280

Published: Nov. 1, 2024

Clozapine is an antipsychotic which was approved in 1989 for treatment-resistant schizophrenia the United States (US). There were few randomized trials before its approval and potentially lethal clozapine adverse drug reactions (ADRs), such as agranulocytosis myocarditis identified by pharmacovigilance. VigiBase, WHO global database, a cornerstone of international pharmacovigilance efforts ADR identification during post-marketing surveillance. This systematic review literature explores additional contributions to knowledge ADRs from recent VigiBase studies.

Language: Английский

Citations

4
Prevalence of obsessive-compulsive symptoms in patients with schizophrenia treated with clozapine: a scoping review DOI Creative Commons

Evelyn Moreno Tarazona,

M. González,

Aurélie Giron

et al.

BMC Psychiatry, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 23, 2025

Abstract Background Schizophrenia is a complex psychiatric disorder, and in patients treated with clozapine, it may induce or exacerbate obsessive-compulsive symptoms (OCS), which negatively affect patients’ quality of life, functionality treatment adherence. Despite its clinical relevance, the reported prevalence characteristics clozapine associated OCS vary widely, limiting effective management. Objective This scoping review synthesizes evidence on schizophrenia explores (types, severity, dose, time to onset/exacerbation). Methods The PRISMA-ScR methodology guided search PubMed, LILACS, Embase, Scielo. Observational studies Spanish, English, Portuguese, French reporting prevalence, incidence, frequency over 18 years were included. Clinical, qualitative studies, those access restrictions excluded. Risk bias was assessed using JBI tools. Results Fourteen included, between 20% 76%, de novo 4.8% 46.4%. Clozapine dose ranged from 196 525 mg/day, duration 5 210 months. most common obsessions aggression checking, severity ranging mild moderate. Conclusions varies widely. Further research needed clarify relationship duration, onset/exacerbation OCS.

Language: Английский

Citations

0
Sex differences in clozapine prescription: results from an Italian 30-year health records registry DOI Creative Commons
Maria Ferrara, Ilaria Domenicano, Alice Bellagamba

et al.

Journal of Psychiatric Research, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Current perspectives on the recognition and management of treatment-resistant schizophrenia: challenges and opportunities DOI
Myrto Samara, Georgios Alevizopoulos,

Vasilis P. Bozikasc

et al.

Expert Review of Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Introduction Treatment-resistant schizophrenia (TRS) significantly impacts patients with schizophrenia, leading to a high disease burden, reduced quality of life, and functional impairment. Many fail respond standard antipsychotic treatments, requiring specialized therapeutic approaches. Clozapine remains the only approved treatment for TRS, demonstrating effectiveness in reducing symptoms, hospitalizations, risk suicide. However, its use is often delayed due concerns about adverse events, need ongoing monitoring.

Language: Английский

Citations

0
Is muscarinic receptor agonist effective and tolerant for schizophrenia? DOI Creative Commons
Xiaonan Guo,

Rongshan Deng,

Jianbo Lai

et al.

BMC Psychiatry, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 2, 2025

Several randomized clinical trials (RCTs) have recently examined the efficacy and tolerability of muscarinic receptor agonists in schizophrenia. However, whether therapeutics targeting receptors improve symptom management reduce side effects remains systemically unexplored. Embase, PubMed, Web Science were searched from inception until Jan 9, 2025. Altogether, safety outcomes four RCTs (397 individuals group, 374 placebo control group) meta-analyzed. To compare scores positive negative syndrome scale (PANSS), response rate, discontinuation adverse events with vs. patients schizophrenia, changes pooled as mean difference (MD) for continuous risk ratio (RR) categorical outcomes. It revealed that superior to terms decrease total PANSS score (MD, - 9.92; 95% CI, -12.46 -7.37; I2 = 0%), subscore 3.21; -4.02 -2.40; -1.79; -2.47 -1.11; 48%). According study-defined RR was 2.08 (95% 1.59 2.72; 0%). No significance found rate. Muscarinic associated a higher nausea (RR 4.61, 2.65 8.02; 3%), particular, xanomeline-trospium risks dyspepsia, vomiting, constipation. The findings highlighted an advantage tolerated event profiles

Language: Английский

Citations

0
Is muscarinic receptor agonist effective and tolerant for schizophrenia? A systematic review and meta-analysis DOI Creative Commons
Xiaonan Guo,

Rongshan Deng,

Jianbo Lai

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 16, 2024

Abstract Background: Several randomized clinical trials (RCTs) have recently examined the efficacy and tolerability of muscarinic receptor agonists in schizophrenia. However, whether therapeutics targeting receptors improve symptom management reduce side effects remains systemically unexplored. Methods: Embase, PubMed, Web Science were searched from inception until May 16, 2024. Altogether, safety outcomes four RCTs (397 individuals group, 374 placebo control group) meta-analyzed. To compare scores positive negative syndrome scale (PANSS), response rate, discontinuation adverse events with vs patients schizophrenia, changes pooled as mean difference (MD) for continuous risk ratio (RR) categorical outcomes. Results: It revealed that superior to terms decrease total PANSS score (MD, − 9.92; 95% CI, -12.46 -7.37; I2 = 0%), subscore 3.21; -4.02 -2.40; -1.79; -2.47 -1.11; 48%). According study-defined RR was 2.08 (95% 1.59 2.72; 0%). No significance found rate. Muscarinic associated a higher nausea (RR 4.61, 2.65 8.02; 3%), particular, xanomeline-trospium risks dyspepsia, vomiting, constipation. Conclusions: The findings highlighted an advantage tolerated event profiles

Language: Английский

Citations

1
A Simple HPLC-DAD Method for the Therapeutic Monitoring of Clozapine and Related Metabolites in Human Plasma and Urine Samples DOI Creative Commons
Mircea-Alexandru Comănescu,

Dana-Maria Preda,

D. S. Miron

et al.

Molecules, Journal Year: 2024, Volume and Issue: 29(21), P. 5039 - 5039

Published: Oct. 25, 2024

Clozapine and its metabolites require close therapeutic monitoring (TDM) in patients due to poor correlation between the administrated doses resulting plasma concentrations, narrow interval, high inter-individual variability, risk of serious side effects once toxic levels are exceeded. The aim study was develop a simple (relatively cheap) LC-UV method for quantification clozapine urine samples. For sample preparation, liquid-liquid extraction (LLE)

Language: Английский

Citations

0
Clinical Characteristics of Inpatients with Schizophrenia Spectrum Disorder Treated with Electroconvulsive Therapy: A Population-Level Cross-Sectional Study: Titre: Caractéristiques cliniques des patients hospitalisés présentant un trouble du spectre de la schizophrénie et traités par électrochocs : Une étude de population transversale DOI
Tyler S. Kaster,

Amreen Babujee,

Isobel Sharpe

et al.

The Canadian Journal of Psychiatry, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 11, 2024

Electroconvulsive therapy (ECT) is an evidence-based treatment for schizophrenia when anti-psychotic medications do not sufficiently control symptoms of psychosis or rapid response required. Little known about how it used in routine clinical practice. The aim this study was to identify the association demographic and characteristics with administration ECT spectrum disorders (SSD).

Language: Английский

Citations

0